All the Drug Class Drugs
Statin. Atorvastatin 10, 20, 40, 80 mg. F.C. TABS: 30 x 10 mg, 20 mg, 40 mg, 80
mg. Prim. hypercholesterolem. incl.
famil. hypercholesterolem.
(heterozygous variant)/comb. (mixed)
hyperlipidemia (Fredrickson types IIa,
IIb): Initial: 10-20 mg 1 x dly. Pts. requir.
large reduct. in LDL (>45%): 40 mg 1 x
dly. Dos. range: 10-80 mg 1 x dly. To be
individualiz. Homozygous famil.
hypercholesterolem: 10-80 mg 1 x dly
as adjuv. to other lipid-lower. tmt or if
such tmts unavail. Heterozygous famil.
hypercholesterolem in ped. pts (10-17
yrs): Initial: 10 mg dly; max: 20 mg dly.
To be individualiz. Prevent. CV/
cerebrovasc. events: 10 mg dly. Higher
dos. may be necessary. Hepat. insuffic:
Perform liver tests bef. initiat. tmt, at 6
and 12 wks aft. initiat./elevat. dose and
periodic. (e.g. semi-annually). Ren.
insuffic: No dose adjust. req. Elderly: As
gen. populat.
Hypercholesterolem: Adjuv. to diet for
reduct. elevat. total cholesterol LDLcholesterol
apolipoprotein B and
triglycerides and to increase HDL
cholesterol in pts with prim.
hypercholesterolem. when response to
diet and other nonpharmacolog.
measures is inadeq; to reduce total-C and
LDL-C in pts. with homozygous familial
hypercholesterolem. as an adjunct to
other lipid-lower. tmt. (e.g. LDL apheres.)
or if such tmts are unavail. Ped. pts (10-17
yrs): Adjuv. to diet to reduce total -C, LDL-C
and apo B levels in boys and
postmenarchal girls with heterozygous
famil. hypercholesterolem. Prevent. CV
dis./cerebrovasc. event: Adjuv. to correct.
other risk factors such as hypertens. Pts.
with clinic. evident coronary heart dis:
Reduce risk of non-fatal MI; reduce risk of
fatal and non fatal stroke; reduce risk of
hospitalizat. for CHF; reduce risk of
angina. Reduce risk revascular. proced.
C/I: Hypersens., active liver dis./
unexplained persist. elevats. serum
transaminases exceeding 3 x upper limit
of normal; myopath., pregn./lact.;
women of childbear. potent. not using
approp. contracept. measures.
Statin. Rosuvastatin (as Calcium) 5, 10, 20, 40 mg. TABS: 28 x 5mg, 10 mg, 20 mg, 40
mg. Not to be chewed, crushed or
divided. May be given at any time of the
day, with or without food. Bef. tmt.
initiat. pt. to be on a standard
cholesterol-lower. diet that should
contin. dur. tmt. Individual. accord. to
the goal of the ther. and pt.
response. Start dose: 10 mg 1 x dly. Dose
adjust. to 20 mg can be made after 4 wks if necess. 40 mg only in pts. with
severe hypercholesterolem. at high CV
risk who do not achieve their tmt. goal
on 20 mg. Follow-up routine to be
performed. Not recommend. for ped.
No dos adjust. necess in elderly, or pts.
with mild to mod. ren. impair. Hepat.
impair. pts. with Child-Pugh scores of 8
and 9: Assess. of ren. funct. should be
considered.
Prim. hypercholesterolem. (type IIa incl.
heterozygous famil.
hypercholesterolem.) or mixed
dyslipidem. (type IIb) as an adjunct to
diet when response to diet and other
non-pharmacolog. tmts. (e.g exercise,
wt. reduct.) is inad. Homozygous famil.
hypercholesterolem. as an adjunct to
diet and other lipid lower. tmts (e.g. LDL
apheres.) or if such tmts. not approp.
C/I: Hypersens. to rosuvastatin or to any of
the excips.; active liver dis. incl.
unexplain., persist. elevat. serum
transaminases and any serum
transaminase elevat. exceed. 3 x the
upper limit of normal (ULN); severe ren.
impair. (creatinine clear. <30ml/min);
myopath. pts. receiv. concom.
cyclosporin; pregn., lact., women of
childbearing potential not using approp.
contracept. measures.
Statin. Atorvastatin (as calcium) 10, 20, 40, 80 mg. F.C. TABS: 30 x 10 mg, 20 mg. Init: 10-20-
mg 1 x dly. Pts requir. larger reduct. in
LDL (more than 45%) may be started
at 40 mg 1 x dly. Adjust. dose at
intervals of 4 wks or more. Max. dose:
80 mg 1 x dly. Doses may be given at
any time of day without regard to
meals. Lipid levels should be analyzed
within 2-4 wks and dose adjust.
accord. See lit.
F.C. TABS: 30 x 40 mg, 80 mg.
Initial: 10 mg 1 x dly. Incr. grad. to max.
80 mg 1 x dly without regard to meals.
Adjunct. to diet for tmt. elevated total
and LDL cholesterol, apo B, triglyc. in pts.
with prim. hypercholesterolem.,
incl.
famil. hypercholesterolem. (heterozyg.)
or combined (mixed) hyperlipidemia
(types IIa, IIb Fredrickson classific.) when
response to diet and other non-pharm.
measures alone has been inad. To reduce
total-C and LDL-C in pts. with homozyg.
famil. hypercholesterolem. as adjunct to
other tmts. Ped: 10-17 yrs: Adjunct to diet
to reduce total-C, LDL-C, apo B levels in
boys and postmenarchal girls with
heterozyg. famil. hypercholesterem. aft.
an adequate trial of diet ther. with foll.
findings: LDL-C remains ≥ 190 mg/dL or
LDL-C remains ≥ 160 mg/dL with
positive fam. history of prem. CV dis. or 2
or more other CVD risk factors present.
Prevent CV and/or cerebrovasc. events
such as MI or stroke. Adjunct to correct
other risk factors such as hypertens. (in
pts with 3 or more additional risk factors
or diabetes with one additional risk
factor.)
C/I: Hypersens., active liver dis.,
unexplained elevat. serum
transaminase, myopathy, pregn., lact.
See lit.
Statin. Atorvastatin (as Calcium) 10, 20, 40, 80 mg. TABS: 30 X 10 mg, 20 mg, 40 mg, 80 mg.
Usual Init dose: 10 or 20mg 1 × dly.
Adjust. Dose at intervals of 4 wks or
more. Max. dose for adults: 80mg 1xdly.
Max. dose for children: 20 mg 1Xdly.
Doses may be given at any time of day
without regard to meals. Lipid levels
should be analyzed within 2-4 wks and
dose adjust. accord. See lit.
Adjunct. to diet for tmt. elevated total
and LDL-cholesterol, apo B triglyc. and
to incr. HDL cholesterol in pts. with
prim. hypercholesterolem., incl. famil.
hypercholesterolem. (heterozyg.) or
combined (mixed) hyperlipidemia
(types IIa, IIb fredrickson classific.) when
response to diet and other non-pharm.
measures alone has been inad. To
reduce total-C and LDL-C in patients
with homozyg. famil.
hypercholesterolem. as adjunct to other
lipid-lower. tmt. (e.g. LDL apheres.) or if
such tmts. unavail. Ped: 10-17 yrs:
Adjunct to diet to reduce total-C, LDL-C,
apo B levels in boys and postmenarchal
girls (10-17 yrs of age) with heterozyg.
famil. hypercholesterolem. aft. an
adequate trial of diet ther. with foll.
findings: LDL-C remains > or = 190 mg/
dl, LDL-C remains > or = 160 mg/dl with
positive fam. history of prem. CV dis. or
two or more other CVD risk factors
present in the pediatric patient. Prevent.
CV and/or cerebrovasc. events such as
MI or stroke. Adjunct to correct other
risk factors such as hypertens. (in pts. with 3 or more additional risk factors or
diabetes with one additional risk factor).
Pts. with clinic. evident coronary heart
dis: Reduce risk of non fatal MI. Reduce
risk of fatal/non fatal stroke. Reduce risk
of revasc. proced. Reduce risk of
hospitalizat. for CHF. Reduce risk of
angina. See lit.
C/I: Hypersens. to Atorvastatin or
ingreds or to similar blood lipid
lowering. Pregn., Lact. and in woman of
childbear. age not using adeq.
contracept. Active or history of liver dis.,
unexplained presistent elevat. serum
transaminase exceeding 3 times the
upper limit of normal. Myopathy. Ped.
under 10 yrs/ premenstruation girls.
Patients that take Cyclosporine,
Telaprevir or a combination of
Tipranavir and Ritronavir. See lit.
Statin. Pravastatin Sodium 10, 20, 40 mg. TABS: 30 x 10 mg, 20 mg,
40 mg. 10-40 mg dly at bedt.
Response within 1-2 wks. Max. effect.
4 wks. Elderly: Initiate at lower dose
and monitor.
Prim. prevent. coron. events: In
hypercholest. pts. to reduce risks of M.I.
revascularizat. and deaths due to CV
causes with no incr. in deaths from non-CV
causes. Second. prevent. CV events: In
hypercholesterolem. pts. incl. prior M.I. to
slow the progress. of coron. atheroscleros.
and reduce the risk of acute coron. events.
In pts. with prev. M.I. to reduce the risk of
recur. M.I., risk of myocard. revasc. proced.,
reduce the risk of stroke or transient
ischem. attacks. In hypercholesterolem.
and mixed dyslipidem. (Frederickson types
lla and llb): As adjunct to diet to reduce
elevat. total cholesterol, LDL - cholesterol
and triglyceride levels.
Statin. Pravastatin Sodium 20 mg, 40 mg. TAB: 30 x 20 mg,
40 mg. Usual dosage range: 10-40
mg dly at bedt. Dose response effect is
apparent within 1-2 wks; Max. effect: 4
wks. Perform periodic lipid determ. at
intervals of not less than 4 wks. and
adjust dosage. Not to be used under 18
yrs of age. Elderly and pts. with hepat.
or ren. impair: Initiate tmt. at the lower
dosage range and monitor pts.
Prim. prevent. coron. events: In
hypercholest. pts. to reduce risks of M.I..
revascularizat. and deaths due to CV causes
with no incr. in deaths from non-CV causes.
Second. prevent. CV events: In
hypercholesterolem. pts. incl. prior M.I. to
slow the progress. of coron. atheroscleros.
and reduce the risk of acute coron. events.
In pts. with prev. M.I. to reduce the risk of recur. M.I., risk of myocard. revasc. proced.,
reduce the risk of stroke or transient ischem.
attacks. In hypercholesterolem. and mixed
dyslipidem. (Frederickson types lla and llb):
As adjunct to diet to reduce elevat. total
cholesterol, LDL - cholesterol and
triglyceride levels.
C/I: Known hypersens. to any ingred.,
pregn., lact.; active liver dis. or
unexplained, persistent elevat. in liver
funct. tests.
